| Retention and adherence: global challenges for the long-term care of adolescents and young adults living with HIV |
24 |
| Altered gut microbiome composition in HIV infection: causes, effects and potential intervention |
21 |
| HIV subtype diversity worldwide |
18 |
| The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research |
17 |
| Chimeric antigen receptor T-cell approaches to HIV cure |
16 |
| Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection |
15 |
| Neutralization tiers of HIV-1 |
14 |
| The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes |
13 |
| Adolescent lives matter: preventing HIV in adolescents |
13 |
| 4-Ethynyl-2-fluoro-2-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor |
13 |
| Antiretroviral implants for treatment and prevention of HIV infection |
13 |
| Inhibitors of the HIV-1 capsid, a target of opportunity |
12 |
| Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials |
11 |
| Impact of antiretroviral drugs on the microbiome: unknown answers to important questions |
11 |
| Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis |
10 |
| Therapeutic vaccination for HIV: hopes and challenges |
10 |
| Differentiated service delivery: navigating the path to scale |
9 |
| Barriers to, and emerging strategies for, HIV testing among adolescents in sub-Saharan Africa |
9 |
| Lessons learned from HIV antiretroviral treatment interruption trials |
9 |
| HIV integration sites and implications for maintenance of the reservoir |
8 |
| Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization? |
8 |
| Strategies for engaging transgender populations in HIV prevention and care |
8 |
| Fostemsavir: a new CD4 attachment inhibitor |
8 |
| The return of PRO a CCR5-directed mAb |
8 |
| Ethical issues in HIV remission trials |
8 |
| Neutralizing antibodies for HIV-1 prevention |
8 |
| Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV |
7 |
| Adolescent transition among young people with perinatal HIV in high-income and low-income settings |
7 |
| Doravirine: a review |
7 |
| The HIV epidemic in Latin America: accomplishments and challenges on treatment and prevention |
7 |
| The arc of HIV epidemics in sub-Saharan Africa: new challenges with concentrating epidemics in the era of 90-90-90 |
6 |
| Humanized mouse models to study pathophysiology and treatment of HIV infection |
6 |
| Challenges of reaching 90-90-90 in the Southern United States |
6 |
| Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
6 |
| Current and future priorities for the development of optimal HIV drugs |
6 |
| Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection |
5 |
| Challenges of TB and HIV co-treatment: updates and insights |
5 |
| Mental health and substance use in HIV-infected adolescents |
5 |
| Youth-friendly services and differentiated models of care are needed to improve outcomes for young people living with HIV |
5 |
| Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies |
5 |
| Rilpivirine long-acting for the prevention and treatment of HIV infection |
5 |
| Bictegravir |
5 |
| Comparative analysis of HIV sequences in real time for public health |
5 |
| Evolving HIV epidemics: the urgent need to refocus on populations with risk |
4 |
| Cancer in adolescents and young adults living with HIV |
4 |
| Recent progress in understanding HIV reservoirs |
4 |
| HIV and aging: role of the microbiome |
4 |
| Fractures and the gut microbiome |
4 |
| Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease |
4 |
| The microbiome and HIV persistence: implications for viral remission and cure |
4 |
